openPR Logo
Press release

Antibodies Market 2026 | , Herceptin, and Humira (AbbVie) are successful drugs in the market. Novartis, Amgen Inc., Biogen Inc

02-01-2019 02:06 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Research Report Insights

Antibodies Market 2026 | , Herceptin, and Humira (AbbVie)

Increasing adoption of therapeutic antibodies along with elevated rate of product approval in developing countries is propelling the growth of the global antibodies market. The market had surpassed US$ 104 Bn in 2016. Additionally, approval of monoclonal antibody products, combined with drug conjugates, antibody fragments, and therapeutic antibodies in key markets of Europe, Japan and the U.S. have boosted the growth of the market as well as inexpensive biosimilar antibody therapeutics available in the market is another driving factor for the market.

However, failure of investigational drugs in late stages of improvement and side effects associated with antibody treatment can be key factors to pose challenge to widespread adoption. Antibodies administration has been linked with acute anaphylaxis and serum sickness, restraining the growth of the market. The global antibodies market is anticipated to expand at CAGR over the forecast period, witnessing to surpass US$ 340 Bn in terms of revenue 2026.

Request For Report Sample: https://www.researchreportinsights.com/report/sample/110114965/Antibodies-Market

Segmental Analysis of Antibodies Market

Monoclonal antibodies segment, by drug type had robust demand in 2016 and secured above 93% market share in terms of revenue. This segment had generated nearly US$ 100 Bn. Antibody drugs complexes and polyclonal antibodies are likely to exhibit minority market share.

Hospitals are likely to remain the largest end-user in the market and accounted for more than 85% market share in terms of revenues in 2016. The hospital end-user segment had exhibited y-o-y growth rate of nearly 13% and surpassed US$ 89 Bn in revenues.

The global antibodies market has been segmented on the basis of disease indication into autoimmune disorders, CNS disorders, cancer and cardiovascular diseases. Cancer was the most leading indication segment, which had accounted for nearly 55% market share in terms of revenues in 2016. In revenues, cardiovascular disease segment was the smallest segment in the antibodies market and had witnessed the lowest growth rate amongst other indication segments.

U.S. to Hold Majority Share of North America Antibodies Market

North America was the largest market for antibodies and had accounted for nearly two-fourth of the revenue share of the global antibodies market in 2016. Therapeutics antibody products are likely to witness submission of biologics licence application (BLA) in the U.S., whereas in Biologics and Genetic Therapies Directorate (BGTD) oversees the biological product’s approval. The U.S. is likely to hold majority share of the North America antibodies market in terms of revenues with highest growth rate than Canada.

Request For Report discount: https://www.researchreportinsights.com/report/discount/110114965/Antibodies-Market

Additionally, APEJ and Western Europe are likely to be the other top antibodies markets. While markets in Germany, France and the U.K. are likely to continue their top position in Western Europe, in APEJ, demand for antibodies is likely to remain largely concentrated in India, ASEAN and China.

Johnson & Johnson, AbbVie Inc., and F. Hoffmann-La Roche AG will continue their position as top 3 players in the global antibodies market. In revenues, these three players collectively generate nearly 56% market share. Remicade (J&J), Avastin (Roche), Herceptin, and Humira (AbbVie) are successful drugs in the market. Novartis, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, and Merck & Co are some other leading players operating in the global antibodies market. Strengthening collaboration with distribution partners and achieving product approval from FDA and EU are key strategy for prominent players in the market.

Report Analysis: https://www.researchreportinsights.com/report/rd/110114965/Antibodies-Market

Research Report Insights (RRI) is a leading market intelligence and consulting firm. We deliver a host of services including custom research reports, syndicated research reports, and consulting services which are personalized in nature. RRI delivers a complete packaged solution to clients; this combines current market intelligence, technology inputs, statistical anecdotes, valuable growth insights, 360-degree view of the competitive framework, and anticipated market trends

Research Report Insights (RRI
42 Joseph Street
Port carling P0B 1J0
Muskoka, Ontario1
Phone - +1-631-721-4201
Website: https://www.researchreportinsights.com/
Email: sales@researchreportinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antibodies Market 2026 | , Herceptin, and Humira (AbbVie) are successful drugs in the market. Novartis, Amgen Inc., Biogen Inc here

News-ID: 1554144 • Views: 202

More Releases from Research Report Insights

Automotive Brake System Market 5.7% of CAGR throughout 2017-2022 Research Report …
The global automotive brake system market is anticipated to witnessing a substantial growth due to fresh prospects of the automotive industry in emerging along with developing economies and increased safety concerns by the government. It was stated in the report that the overall growth of the market is expected to reach a market value of above US$ 25 Billion through 2022, exhibiting a strong 5.7% of CAGR throughout 2017-2022. In modern
Automotive Brake System Market 2022 | Continental AG, Robert Bosch GmbH, Wabco H …
The global automotive brake system market is anticipated to witnessing a substantial growth due to fresh prospects of the automotive industry in emerging along with developing economies and increased safety concerns by the government. It was stated in the report that the overall growth of the market is expected to reach a market value of above US$ 25 Billion through 2022, exhibiting a strong 5.7% of CAGR throughout 2017-2022. In modern
Tarpaulin Sheets Market These factors, thus, are likely to boost the plastic mar …
A tarpaulin is a big sheet of water-proof material available in various sizes, generally being crafted from plastic like HDPE, LDPE. Tarps can be used to refuge any kind of items. Tarpaulins can efficiently be used to cover goods in the course of shipping and then they also can be used to house goods internal of a truck body so they are not uncovered to the elements. The Tarpaulin Sheets Market
Research Report Insights present kayaks market by 21 percent, or over by $42 mil …
Kayaking is a watersport which involves paddling using a double-bladed oar and a small boat known as a kayak. The boats come in a variety of sizes and types, depending on their intended use, but most kayaks feature an enclosed deck which covers the legs. The boat sits low in the water & usually only accommodates the single paddler, but tandem kayaks hold two people and some boats hold three

All 5 Releases


More Releases for Antibodies

Bispecific Antibodies Market Opportunity Analysis, 2018-2026
Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies are emerging a
Anti-Infective Antibodies Market Analysis & Trends 2020
Anti-infective antibodies are being used extensively nowadays to treat serious bacterial and viral diseases such as pneumonia, tuberculosis and malaria. According to the World Health Organization, six major infectious diseases namely diarrhea, pneumonia, malaria, acquired immune deficiency syndrome (AIDS) , measles and tuberculosis are responsible for half of the premature deaths worldwide killing children and young adults. Report Overview @ https://www.transparencymarketresearch.com/anti-infective-antibodies-market.html Moreover, threatening pandemics such as H1N1 influenza A virus (swine
Global Monoclonal Antibodies Pipeline Analysis
The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future. There has been a
Global Monoclonal Antibodies Pipeline Insight 2015
Ever since the Nobel Prize was bestowed on the person who invented the technology which enabled the preparation of monoclonal antibodies in 1984, their use has considerably expanded far beyond the scientific realm. Paul Ehrlich framed a hypothesis that a “magic bullet” could be developed with an objective of targeting selective diseases. With the introduction and development of hybridoma technology by Kohler and Milstein, this hypothesis has become a reality.
Global Cancer Monoclonal Antibodies Market & Pipeline Insight
The recent years have witnessed the emergence of monoclonal antibodies, which has the potential to offer less toxic and more efficient therapeutic alternatives for patients. Over the past decades, the researchers have increased their learning about the human body’s immune system, which has led to the achievement of significant number of regulatory milestones during this period. The use of mAbs for treating cancer has increased significantly. The rising market availability
Bispecific Antibodies Market to Grow Globally
Bispecific Antibodies Market Overview Bispecific antibody (BsAb) is an artificial protein that is composed of fragments of two different monoclonal antibodies and has ability to bind to two different types of antigen. Cancer immunotherapy is the most widely explored application of bispecific antibody. Lung, breast and colon cancer are the wider applications of BsAb. Bispecific antibody simultaneously binds to a cytotoxic cell and target tumor cell and destroys it. Bispecific antibodies